

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 October 2001 (18.10.2001)

PCT

(10) International Publication Number
WO 01/76573 A2

- (51) International Patent Classification⁷: **A61K 31/00**
- (21) International Application Number: PCT/EP01/04115
- (22) International Filing Date: 10 April 2001 (10.04.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/196,743 12 April 2000 (12.04.2000) US
- (71) Applicant (for all designated States except AT, US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).
- (71) Applicant (for AT only): **NOVARTIS-ERFINDUNGEN** [AT/AT]; VERWALTUNGSGESELLSCHAFT m.b.H., Brunner Strasse 59, A-1235 Vienna (AT).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **DE GASPARO, Marc** [CH/CH]; Es Planches 123a, CH-2842 Rossemaison (CH). **GRAVES, Kurt, C.** [US/US]; 4 Woodhull Drive, Chester, NJ 07930 (US).
- (74) Agent: **BECKER, Konrad**; Novartis AG, Corporate Intellectual Property, Patent & Trademark Dept., CH-4002 Basel (CH).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: COMBINATION OF ORGANIC COMPOUNDS

(57) Abstract: The invention relates to a combination of at least two therapeutic combination components selected from the group consisting of (i) an AT₁-receptor antagonist or an AT₁ receptor antagonist combined with a diuretic or, in each case, a pharmaceutically acceptable salt thereof, (ii) a HMG-Co-A reductase inhibitor or a pharmaceutically acceptable salt thereof and (iii) an ACE inhibitor or a pharmaceutically acceptable salt thereof for use in the prevention of, delay of progression of, treatment of selected diseases and conditions.



WO 01/76573 A2

Combination of Organic Compounds

The invention relates to a combination of at least two therapeutic combination components selected from the group consisting of

- (i) an AT₁-receptor antagonist or an AT₁ receptor antagonist combined with a diuretic or, in each case, a pharmaceutically acceptable salt thereof,
- (ii) a HMG-Co-A reductase inhibitor or a pharmaceutically acceptable salt thereof and
- (iii) an ACE inhibitor or a pharmaceutically acceptable salt thereof

for use in the prevention of, delay of progression of, treatment of a disease or condition selected from the group consisting of hyperlipidaemia and dyslipidemia, atherosclerosis, insulin resistance and syndrome X, diabetes mellitus type 2, obesity, nephropathy, renal failure, e.g. chronic renal failure, hypothyroidism, survival post myocardial infarction (MI), coronary heart diseases, hypertension in the elderly, familial dyslipidemic hypertension, and remodeling following hypertension (antiproliferative effect of the combination), all these diseases or conditions associated with or without hypertension, and, furthermore, in the prevention of, delay of progression of, treatment of stroke, erectile dysfunction and vascular disease.

The invention furthermore relates to a pharmaceutical composition for the prevention of, delay of progression of, treatment of a disease or condition selected from the group consisting of hyperlipidaemia and dyslipidemia, atherosclerosis, insulin resistance and syndrome X, diabetes mellitus type 2, obesity, nephropathy, renal failure, e.g. chronic renal failure, hypothyroidism, survival post MI, coronary heart diseases, hypertension in the elderly, familial dyslipidemic hypertension, and remodeling following hypertension (antiproliferative effect of the combination), all these diseases or conditions associated with or without hypertension, and, furthermore, for the prevention of, delay of progression of, treatment of stroke, erectile dysfunction and vascular disease, comprising

(a) a combination of at least two therapeutic combination components selected from the group consisting of

- (i) an AT₁-receptor antagonist or an AT₁ receptor antagonist combined with a diuretic or, in each case, a pharmaceutically acceptable salt thereof,
- (ii) a HMG-Co-A reductase inhibitor or a pharmaceutically acceptable salt thereof and
- (iii) an ACE inhibitor or a pharmaceutically acceptable salt thereof, and

- 2 -

(b) a carrier.

The invention furthermore relates to a method of prevention of, delay of progression of or treatment of endothelial dysfunction with or without hypertension comprising administering to a warm-blooded animal, including man, in need thereof an effective amount of an AT₁ receptor antagonist or a pharmaceutically acceptable salt thereof or of a combination of an AT₁ receptor antagonist and an diuretic or a pharmaceutically acceptable salt thereof.

The invention furthermore relates to a method of prevention of, delay of progression of or treatment of endothelial dysfunction with or without hypertension comprising administering to a warm-blooded animal, including man, in need thereof an effective amount of a HMG-Co-A reductase inhibitor or a pharmaceutically acceptable salt thereof.

The invention furthermore relates to a method of prevention of, delay of progression of or treatment of endothelial dysfunction with or without hypertension comprising administering to a warm-blooded animal, including man, in need thereof an effective amount of an ACE inhibitor or a pharmaceutically acceptable salt thereof.

The invention furthermore relates to a method of prevention of, delay of progression of or treatment of endothelial dysfunction with or without hypertension comprising administering to a warm-blooded animal, including man, in need thereof a pharmaceutical composition comprising

a combination of at least two therapeutic agents selected from the group consisting of

- (i) an AT₁-receptor antagonist or a pharmaceutically acceptable salt thereof,
- (ii) a HMG-Co-A reductase inhibitor or a pharmaceutically acceptable salt thereof and
- (iii) an ACEI inhibitor or a pharmaceutically acceptable salt thereof.

The invention furthermore relates to the use of

(a) either of

- (i) an AT₁-receptor antagonist or a pharmaceutically acceptable salt thereof,
- (ii) a HMG-Co-A reductase inhibitor or a pharmaceutically acceptable salt thereof or
- (iii) an ACEI inhibitor or a pharmaceutically acceptable salt thereof; or

(b) a combination of

- (i) an AT₁-receptor antagonist or a pharmaceutically acceptable salt thereof,

- 3 -


- (ii) a HMG-Co-A reductase inhibitor or a pharmaceutically acceptable salt thereof or
- (iii) an ACEI inhibitor or a pharmaceutically acceptable salt thereof

for the manufacture of a medicament for the prevention of, delay of progression of, or treatment of

- (α) a disease or condition selected from the group consisting of hyperlipidaemia and dyslipidemia, atherosclerosis, insulin resistance and syndrome X, diabetes mellitus type 2, obesity, nephropathy, renal failure, e.g. chronic renal failure, hypothyroidism, survival post MI, coronary heart diseases, hypertension in the elderly, familial dyslipidemic hypertension, and remodeling following hypertension (antiproliferative effect of the combination), all these diseases or conditions associated with or without hypertension; or
- (β) endothelial dysfunction with or without hypertension; and
- (γ) stroke, erectile dysfunction and vascular disease.


AT₁-receptor antagonists (also called angiotensin II receptor antagonists) are understood to be those active ingredients which bind to the AT₁-receptor subtype of angiotensin II receptor but do not result in activation of the receptor. As a consequence of the inhibition of the AT₁ receptor, these antagonists can, for example, be employed as antihypertensives or for treating congestive heart failure.

The class of AT₁ receptor antagonists comprises compounds having differing structural features, essentially preferred are the non-peptidic ones. For example, mention may be made of the compounds which are selected from the group consisting of valsartan, losartan, candesartan, eprosartan, irbesartan, saprisartan, tasosartan, telmisartan, the compound with the designation E-1477 of the following formula




- 4 -

the compound with the designation SC-52458 of the following formula



and the compound with the designation ZD-8731 of the following formula



or, in each case, a pharmaceutically acceptable salt thereof.

Preferred AT_1 -receptor antagonist are those agents which have been marketed, most preferred is valsartan or a pharmaceutically acceptable salt thereof.

A diuretic is, for example, a thiazide derivative selected from the group consisting of chlorothiazide, hydrochlorothiazide, methylclothiazide, and chlorothalidon. The most preferred is hydrochlorothiazide.

A preferred combination component "AT₁ receptor antagonist combined with a diuretic" is a combination of valsartan or losartan or, in each case, a pharmaceutically acceptable salt thereof and hydrochlorothiazide.

HMG-Co-A reductase inhibitors (also called β -hydroxy- β -methylglutaryl-co-enzyme-A reductase inhibitors) are understood to be those active agents which may be used to lower the lipid levels including cholesterol in blood.

The class of HMG-Co-A reductase inhibitors comprises compounds having differing structural features. For example, mention may be made of the compounds which are selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, pitavastatin (formerly itavastatin), pravastatin, rosuvastatin, and simvastatin, or, in each case, a pharmaceutically acceptable salt thereof.

Preferred HMG-Co-A reductase inhibitors are those agents which have been marketed, most preferred is fluvastatin, atorvastatin, pitavastatin or simvastatin or a pharmaceutically acceptable salt thereof.

The interruption of the enzymatic degradation of angiotensin I to angiotensin II with so-called ACE-inhibitors (also called angiotensin converting enzyme inhibitors) is a successful variant for the regulation of blood pressure and thus also makes available a therapeutic method for the treatment of congestive heart failure.

The class of ACE inhibitors comprises compounds having differing structural features. For example, mention may be made of the compounds which are selected from the group consisting of alacepril, benazepril, benazeprilat, captopril, ceronapril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, imidapril, lisinopril, moveltopril, perindopril, quinapril, ramipril, spirapril, temocapril, andtrandolapril, or, in each case, a pharmaceutically acceptable salt thereof.

Preferred ACE inhibitors are those agents which have been marketed, most preferred are benazepril and enalapril.

A preferred composition comprises the combination of (i) the AT₁ receptor antagonist valsartan or a pharmaceutically acceptable salt thereof and (ii) a HMG-Co-A reductase inhibitor selected from the group consisting of fluvastatin, atorvastatin, pitavastatin and simvastatin or, in each case, a pharmaceutically acceptable salt thereof. Most preferred is the composition comprising (i) valsartan or a pharmaceutically acceptable salt thereof and

(ii) pitavastatin or simvastatin or, in each case, a pharmaceutically acceptable salt thereof. Likewise preferred is a corresponding composition where valsartan is replaced with a combination of valsartan with hydrochlorothiazide.

A preferred composition comprises the combination of (i) the AT₁ receptor antagonist valsartan or a pharmaceutically acceptable salt thereof and (ii) the ACE inhibitor benazepril or enalapril or, in each case, a pharmaceutically acceptable salt thereof.

A preferred composition comprises the combination of (i) a HMG-Co-A reductase inhibitor selected from the group consisting of fluvastatin, atorvastatin, pitavastatin and simvastatin or, in each case, a pharmaceutically acceptable salt thereof and (ii) the ACE inhibitor benazepril or enalapril or, in each case, a pharmaceutically acceptable salt thereof. Most preferred is the composition comprising (i) pitavastatin or simvastatin or, in each case, a pharmaceutically acceptable salt thereof and (ii) benazepril or enalapril or, in each case, a pharmaceutically acceptable salt thereof. Likewise preferred is a corresponding composition where valsartan is replaced with a combination of valsartan with hydrochlorothiazide.

The structure of the active agents identified hereinbefore or hereinafter by generic or tradenames may be taken from the actual edition of the standard compendium "The Merck Index" or from databases, e.g. Patents International (e.g. IMS World Publications). The corresponding content thereof is hereby incorporated by reference. Any person skilled in the art is fully enabled to identify the active agents and, based on these references, likewise enabled to manufacture and test the pharmaceutical indications and properties in standard test models, both in vitro and in vivo.

The corresponding active ingredients or a pharmaceutically acceptable salts thereof may also be used in form of a solvate, such as a hydrate or including other solvents, used for crystallization.

The compounds to be combined can be present as pharmaceutically acceptable salts. If these compounds have, for example, at least one basic center, they can form acid addition salts. Corresponding acid addition salts can also be formed having, if desired, an

additionally present basic center. The compounds having an acid group (for example COOH) can also form salts with bases.

The pharmaceutical activities as effected by administration of representatives of the class of AT₁-receptor antagonists or ACE inhibitors, respectively, or of the combination of active agents used according to the present invention can be demonstrated e.g. by using corresponding pharmacological models known in the pertinent art. The person skilled in the pertinent art is fully enabled to select a relevant animal test model to prove the hereinbefore and hereinafter indicated therapeutic indications and beneficial effects.

Endothelial dysfunction is being acknowledged as a critical factor in vascular diseases. The endothelium plays a bimodal role as the source of various hormones or by-products with opposing effects: vasodilation and vasoconstriction, inhibition or promotion of growth, fibrinolysis or thrombogenesis, production of anti-oxidants or oxidising agents. Genetically predisposed hypertensive animals with endothelial dysfunction constitute a valid model for assessing the efficacy of a cardiovascular therapy.

Endothelial dysfunction is characterized by, for example, increased oxidative stress, causing decreased nitric oxide, increased factors involved in coagulation or fibrinolysis such as plasminogen activating inhibitor-1 (PAI-1), tissue factor (TF), tissue plasminogen activator (tPA), increased adhesion molecules such as ICAM and VCAM, increased growth factors such as bFGF, TGF β , PDGF, VEGF, all factors causing cell growth inflammation and fibrosis.

The treatment e.g. of endothelial dysfunction can be demonstrated in the following pharmacological test:

Material and methods

Male 20-24 week-old SHR, purchased from RCC Ltd (Fullingsdorf, Switzerland), are maintained in a temperature- and light-controlled room with free access to rat chow (Nafag 9331, Gossau, Switzerland) and tap water. The experiment is performed in accordance with the NIH guidelines and approved by the Canton Veterinary office (Bew 161, Kantonales Veterinäramt, Liestal, Switzerland). All rats are treated with the NO synthase

inhibitor L-NAME (Sigma Chemicals) administered in drinking water (50 mg/l) for 12 weeks. The average daily dose of L-NAME calculated from the water consumed was 2.5 mg/kg/d (range 2.1-2.7).

The rats are divided into 5 groups: group 1, control (n = 40); Group 2, valsartan (val5, 5 mg/kg/d; n = 40); Group 3, enalapril (ena1, 1 mg/kg/d; n = 30); Group 4, a combination (ena1val5) of enalapril (1 mg/kg/d) and valsartan (5 mg/kg/d); n = 30 and Group 5, valsartan (val50, 50 mg/kg/d; n = 30). The drugs are administered in drinking fluid. The dose of enalapril was selected from the work of Sweet et al. (1987) indicating significantly increased survival in rats with healed myocardial infarction. The pressor effect of Ang II at 1 mg/kg obtained in controls normotensive rats is reduced by 49 % and 73 % after treatment with valsartan 5 and 50 mg/kg/d , respectively (Gervais et al. 1999). The response to Ang I injected in Wistar Kyoto rats pretreated with enalapril 1 mg/kg/d or valsartan 5 mg/kg/d is similar.

Body weight is measured every week. Systolic blood pressure and heart rate are recorded by tail cuff plethysmography 3 and 2 weeks before starting the study and at 2 weeks after drug administration. Urine is collected over a 24 hour period from rats kept in individual (metabolic) cages the week before starting treatment and at weeks 4 and 12 for volume measurement and protein, creatinine, sodium and potassium determination using standard laboratory methods. At the same time points, blood samples are withdrawn from the retro-orbital plexus (maximum 1 ml) for creatinine, Na⁺ and K⁺ assays.

Ten rats from each group are sacrificed at 4 weeks for collection of kidney and heart for morphological analysis. The remaining rats are sacrificed at 12 weeks. Cardiac and kidney weight is recorded. Terminal blood sampling is performed in 5 % EDTA at 4 (morphometry study) and 12 (end of the study) weeks for aldosterone, determination by radioimmunoassay using a DPC coat-a-count aldosterone-RIA kit (Bühlmann, Switzerland).

Statistical analysis:

All data are expressed as mean \pm SEM. Statistical analysis is performed using a one-way ANOVA, followed by a Duncan's multiple range test and a Newman-Keuls test, 7for comparison between the different groups. Results with a probability value of less than 0.05 are deemed statistically significant.

Results:

Even at non-blood pressure reducing doses, both valsartan and enalapril treatment led to significant improvements in survival rates (67 % and 55 %, respectively). Combining the AT₁-receptor blocker and the ACE inhibitor led to an even more dramatic increase in survival rate to 85 %. Again, this benefit occurred without affecting blood pressure, which remained around 275 mmHg. A high dose of valsartan (50 mg/kg) which significantly attenuated the increase in blood pressure (systolic blood pressure above 250 mmHg), led to a 95 % survival rate. Untreated animals with chronic NO synthase blockade had a mortality rate of 63 % within 12 weeks.

In untreated animals, the high mortality can be attributed principally to the development of malignant hypertension and endothelial dysfunction. The more than additive effects on survival from AT₁-receptor blocker and the ACE inhibitor in non-hypotensive doses might be related to a more complete blockade of the tissue RAS, independent of any effect on blood pressure.

The surprising observation is that, in this model, blockade of the RAS with low doses of valsartan and enalapril improved survival despite persistent kidney dysfunction and high blood pressure. There was no decrease in proteinuria and no reduction of kidney lesions. Kidney and heart sections showed glomerulosclerosis, fibrinoid necrosis and fibrosis. These results clearly demonstrate that survival of SHR with endothelial dysfunction is independent of the blood-pressure lowering effect of the treatment and may be related to a direct effect on the endothelium.

An improvement of regression of atherosclerosis without effecting the serum lipid levels can, for example, be demonstrated by using the animal model as disclosed by H. Kano et al. in Biochemical and Biophysical Research Communications 259, 414-419 (1999).

That the compounds or combinations according to the present invention can be used for the regression of a cholesterol diet-induced atherosclerosis, can be demonstrated using the test model described, e.g., by C. Jiang et al. in Br. J. Pharmacol. (1991), 104, 1033-1037.

That the compounds or combinations according to the present invention can be used for the treatment of renal failure, especially chronic renal failure, can be demonstrated using the test model described, e.g., by D. Cohen et al. in Journal of Cardiovascular Pharmacology, 32: 87-95 (1998).

Further benefits when applying the composition of the present invention are that lower doses of the individual drugs to be combined according to the present invention can be used to reduce the dosage, for example, that the dosages need not only often be smaller but are also applied less frequently, or can be used in order to diminish the incidence of side effects. This is in accordance with the desires and requirements of the patients to be treated.

All the more surprising is the experimental finding that the combined administration of combination according to the present invention results in a beneficial, especially a synergistic (= more than additive effect), therapeutic effect, furthermore, in benefits resulting from the combined treatment and further surprising beneficial effects compared to a monotherapy applying only one of the pharmaceutically active compounds used in the combinations disclosed herein.

In particular, all the more surprising is the experimental finding that the combination of the present invention results in a beneficial, especially a synergistic, therapeutic effect but also in benefits resulting from combined treatment such as a surprising prolongation of efficacy, a broader variety of therapeutic treatment and surprising beneficial effects on diseases and conditions as specified hereinbefore or hereinafter.

Further benefits when applying the composition of the present invention are that lower doses of the individual drugs to be combined according to the present invention can be used to reduce the dosage, for example, that the dosages need not only often be smaller but are also applied less frequently, or can be used in order to diminish the incidence of side effects. This is in accordance with the desires and requirements of the patients to be treated.

Preferably, the jointly therapeutically effective amounts of the active agents according to the combination of the present invention can be administered simultaneously or sequentially in any order, separately or in a fixed combination.

The pharmaceutical composition according to the present invention as described hereinbefore and hereinafter may be used for simultaneous use or sequential use in any order, for separate use or as a fixed combination.

The present invention likewise relates to a "kit-of-parts", for example, in the sense that the components to be combined according to the present invention can be dosed independently or by use of different fixed combinations with distinguished amounts of the components, i.e. simultaneously or at different time points. The parts of the kit of parts can then e.g. be administered simultaneously or chronologically staggered, that is at different time points and with equal or different time intervals for any part of the kit of parts. Preferably, the time intervals are chosen such that the effect on the treated disease or condition in the combined use of the parts is larger than the effect that would be obtained by use of only any one of the components.

The invention furthermore relates to a commercial package comprising the combination according to the present invention together with instructions for simultaneous, separate or sequential use.

These pharmaceutical preparations are for enteral, such as oral, and also rectal or parenteral, administration to homeotherms, with the preparations comprising the pharmacological active compound either alone or together with customary pharmaceutical auxiliary substances. For example, the pharmaceutical preparations consist of from about 0.1 % to 90 %, preferably of from about 1 % to about 80 %, of the active compound. Pharmaceutical preparations for enteral or parenteral, and also for ocular, administration are, for example, in unit dose forms, such as coated tablets, tablets, capsules or suppositories and also ampoules. These are prepared in a manner which is known per se, for example using conventional mixing, granulation, coating, solubilizing or lyophilizing processes. Thus, pharmaceutical preparations for oral use can be obtained by combining the active compound with solid excipients, if desired granulating a mixture which has been

obtained, and, if required or necessary, processing the mixture or granulate into tablets or coated tablet cores after having added suitable auxiliary substances.

The dosage of the active compound can depend on a variety of factors, such as mode of administration, homeothermic species, age and/or individual condition.

Preferred dosages for the active ingredients of the pharmaceutical combination according to the present invention are therapeutically effective dosages, especially those which are commercially available.

Normally, in the case of oral administration, an approximate daily dose of from about 1 mg to about 360 mg is to be estimated e.g. for a patient of approximately 75 kg in weight.

The dosage of the active compound can depend on a variety of factors, such as mode of administration, homeothermic species, age and/or individual condition.

Valsartan, as a representative of the class of AT₁-receptor antagonists, will be supplied in the form of suitable dosage unit form, for example, a capsule or tablet, and comprising a therapeutically effective amount, e.g. from about 20 to about 320 mg, of valsartan which may be applied to patients. The application of the active ingredient may occur up to three times a day, starting e.g. with a daily dose of 20 mg or 40 mg of valsartan, increasing via 80 mg daily and further to 160 mg daily up to 320 mg daily. Preferably, valsartan is applied twice a day with a dose of 80 mg or 160 mg, respectively, each. Corresponding doses may be taken, for example, in the morning, at mid-day or in the evening.

In case of HMG-Co-A reductase inhibitors, preferred dosage unit forms of HMG-Co-A reductase inhibitors are, for example, tablets or capsules comprising e.g. from about 5 mg to about 120 mg, preferably, when using fluvastatin, for example, 20 mg, 40 mg or 80 mg (equivalent to the free acid) of fluvastatin, for example, administered once a day.

In case of ACE inhibitors, preferred dosage unit forms of ACE inhibitors are, for example, tablets or capsules comprising e.g. from about 5 mg to about 20 mg, preferably 5 mg, 10 mg, 20 mg or 40 mg, of benazepril; from about 6.5 mg to 100 mg, preferably 6.25 mg, 12.5 mg, 25 mg, 50 mg, 75 mg or 100 mg, of captopril; from about 2.5 mg to about 20 mg,

preferably 2.5 mg, 5 mg, 10 mg or 20 mg, of enalapril; from about 10 mg to about 20 mg, preferably 10 mg or 20 mg, of fosinopril; from about 2.5 mg to about 4 mg, preferably 2 mg or 4 mg, of perindopril; from about 5 mg to about 20 mg, preferably 5 mg, 10 mg or 20 mg, of quinapril; or from about 1.25 mg to about 5 mg, preferably 1.25 mg, 2.5 mg, or 5 mg, of ramipril. Preferred is t.i.d. administration.

Especially preferred are low dose combinations.

The following examples illustrate the above-described invention; however, it is not intended to restrict the scope of this invention in any manner.

Formulation Example 1:

Film-Coated Tablets:

Components	Composition Per Unit (mg)	Standards
Granulation		
Valsartan [= active ingredient]	80.00	
Microcrystalline cellulose/ Avicel PH 102	54.00	NF, Ph. Eur
Crospovidone	20.00	NF, Ph. Eur
Colloidal anhydrous silica / colloidal silicon dioxide / Aerosil 200	0.75	Ph. Eur/ NF
Magnesium stearate	2.5	NF, Ph. Eur
Blending		
Colloidal anhydrous silica / colloidal silicon dioxide / Aerosil 200	0.75	Ph. Eur/ NF
Magnesium stearate	2.00	NF, Ph. Eur
Coating		
Purified water ^{*)}	-	
DIOLACK pale red 00F34899	7.00	
Total tablet mass	167.00	

^{*)} Removed during processing.

The film-coated tablet is manufactured e.g. as follows:

A mixture of valsartan, microcrystalline cellulose, crospovidone, part of the colloidal anhydrous silica/colloidal silicon dioxide/Aerosile 200, silicon dioxide and magnesium stearate is premixed in a diffusion mixer and then sieve through a screening mill. The resulting mixture is again pre-mixed in a diffusion mixer, compacted in a roller compacter and then sieve through a screening mill. To the resulting mixture, the rest of the colloidal anhydrous silica/colloidal silicon dioxide/Aerosile 200 are added and the final blend is made in a diffusion mixer. The whole mixture is compressed in a rotary tableting machine and the tablettts are coated with a film by using Diolack pale red in a perforated pan.

Formulation Example 2:

Film-coated tablets:

Components	Compostion Per Unit (mg)	Standards
Granulation		
Valsartan [= active ingredient]	160.00	
Microcrystalline cellulose/ Avicel PH 102	108.00	NF, Ph. Eur
Crospovidone	40.00	NF, Ph. Eur
Colloidal anhydrous silica / colloidal silicon dioxide / Aerosil 200	1.50	Ph. Eur/ NF
Magnesium stearate	5.00	NF, Ph. Eur
Blending		
Colloidal anhydrous silica / colloidal silicon dioxide / Aerosil 200	1.50	Ph. Eur/ NF
Magnesium stearate	4.00	NF, Ph. Eur
Coating		
Opadry Light Brown 00F33172	10.00	
Total tablet mass	330.00	

The film-coated tablet is manufactured e.g. as described in Formulation Example 1.

Formulation Example 3:

Film-Coated Tablets:

Components	Composition Per Unit (mg)	Standards
Core: Internal phase		
Valsartan [= active ingredient]	40.00	
Silica, colloidal anhydrous (Colloidal silicon dioxide) [= Glidant]	1.00	Ph. Eur, USP/NF
Magnesium stearate [= Lubricant]	2.00	USP/NF
Crospovidone [Disintegrant]	20.00	Ph. Eur
Microcrystalline cellulose [= Binding agent]	124.00	USP/NF
External phase		
Silica, colloidal anhydrous, (Colloidal silicon dioxide) [= Glidant]	1.00	Ph. Eur, USP/NF
Magnesium stearate [Lubricant]	2.00	USP/NF
Film coating		
Opadry® brown OOF 16711 ^{*)}	9.40	
Purified Water ^{**)}	-	
Total tablet mass	199.44	

^{*)} The composition of the Opadry® brown OOF16711 coloring agent is tabulated below.

^{**)} Removed during processing

Opadry® Composition:

Ingredient	Approximate % Composition
Iron oxide, black (C.I. No. 77499, E 172)	0.50
Iron oxide, brown (C.I. No. 77499, E 172)	0.50
Iron oxide, red (C.I. No. 77491, E 172)	0.50
Iron oxide, yellow (C.I. No. 77492, E 172)	0.50
Macrogolum (Ph. Eur)	4.00
Titanium dioxide (C.I. No. 77891, E 171)	14.00
Hypromellose (Ph. Eur)	80.00

The film-coated tablet is manufactured e.g. as described in Formulation Example 1.

Formulation Example 4:

Capsules:

Components	Composition Per Unit (mg)
Valsartan [= active ingredient]	80.00
Microcrystalline cellulose	25.10
Crospovidone	13.00
Povidone	12.50
Magnesium stearate	1.30
Sodium lauryl sulphate	0.60
Shell	
Iron oxide, red (C.I. No. 77491, EC No. E 172)	0.123
Iron oxide, yellow (C.I. No. 77492, EC No. E 172)	0.123
Iron oxide, black (C.I. No. 77499, EC No. E 172)	0.245
Titanium dioxide	1.540
Gelatin	74.969
Total tablet mass	209.50

The tablet is manufactured e.g. as follows:

Granulation/Drying

Valsartan and microcrystallin cellulose are spray-granulated in a fluidised bed granulator with a granulating solution consisting of povidone and sodium lauryl sulphate dissolved in purified water. The granulate obtained is dried in a fluidised bed dryer.

Milling/Blending

The dried granulate is milled together with crospovidone and magnesium stearate. The mass is then blended in a conical screw type mixer for approximately 10 minutes.

Encapsulation

The empty hard gelatin capsules are filled with the blended bulk granules under controlled temperature and humidity conditions. The filled capsules are dedusted, visually inspected, weightchecked and quarantined until by Quality assurance department.

Formulation Example 5:

Capsules:

Components	Composition Per Unit (mg)
Valsartan [= active ingredient]	160.00
Microcrystalline cellulose	50.20
Crospovidone	26.00
Povidone	25.00
Magnesium stearate	2.60
Sodium lauryl sulphate	1.20
Shell	
Iron oxide, red (C.I. No. 77491, EC No. E 172)	0.123
Iron oxide, yellow (C.I. No. 77492, EC No. E 172)	0.123
Iron oxide, black (C.I. No. 77499, EC No. E 172)	0.245
Titanium dioxide	1.540
Gelatin	74.969
Total tablet mass	342.00

The formulation is manufactured e.g. as described in Formulation Example 4.

Formulation Example 6:

Hard Gelatine Capsule:

Components	Composition Per Unit (mg)
Valsartan [= active ingredient]	80.00
Sodium laurylsulphate	0.60
Magnesium stearate	1.30
Povidone	12.50
Crospovidone	13.00
Microcrystalline cellulose	21.10
Total tablet mass	130.00

Examples 7 to 11:

Example	7	8	9	10	11
Components	Amount per Unit (mg)	Amount per Unit (mg)	Amount per Unit (mg)	Amount per Unit (mg)	Amount per Unit (mg)
Granulation					
Valsartan Drug Substance	80.000	160.000	40.000	320.000	320.000
Microcrystalline Cellulose (NF, Ph.Eur.)/ Avicel PH 102	54.000	108.000	27.000	216.000	216.000
Crospovidone (NF, Ph.Eur.)	15.000	30.000	7.500	80.000	60.000
Colloidal Anhydrous Silica (Ph. Eur.)/Colloidal Silicon Dioxide (NF)/Aerosil 200	1.500	3.000	0.750	3.000	6.000
Magnesium Stearate (NF, Ph.Eur.)	3.000	6.000	1.500	10.000	12.000
Blending					
Colloidal Anhydrous Silica (Ph. Eur.)/Colloidal Silicon Dioxide (NF)/Aerosil 200	---	---	---	3.000	-
Magnesium Stearate, NF, Ph.Eur.	1.500	3.000	0.750	8.000	6.000
Core Weight/mg	155.000	310.000	77.500	640.000	620.000
Coating	-	-	3.800	15.000	16.000

Example 12:

Hard gelatin capsule:

Component	Amount per unit [mg]
Capsule	
Fluvastatin Sodium ¹⁾	21.481 ²⁾
Calcium Carbonate	62.840
Sodium Bicarbonate	2.000
Microcrystalline Cellulose	57.220
Pregelatinized Starch	41.900
Purified Water ³⁾	Q.S.
Magnesium Stearate	1.050
Talc	9.430
Target Capsule Fill Weight	195.92
Capsule Shell	
Hard gelatin Capsule Shell	48.500
Branding Ink (pre-printed)	
White Ink	Trace
Red Ink	Trace
Target Capsule Weight	244.42

¹⁾ includes a 2% overage for moisture²⁾ 20 mg of free acid is equivalent to 21.06 mg Na salt³⁾ partially removed during processing

Example 13:

Hard gelatin capsule

Component	Amount per unit [mg]
Fluvastatin Sodium	42.962 ^{1) 2)}
Calcium Carbonate	125.680
Sodium Bicarbonate	4.000
Microcrystalline Cellulose	114.440
Pregelatinized Starch	83.800
Purified Water ³⁾	Q.S.
Magnesium Stearate	2.100
Talc	18.860
Target Capsule Fill Weight	391.840
Capsule Shell	
Hard gelatin Capsule Shell	76.500
Branding Ink (pre-printed)	
White Ink	Trace
Red Ink	Trace
Target Capsule Weight	468.34

¹⁾ includes a 2% overage for moisture²⁾ 20 mg of free acid equivalent to 21.06 mg Na salt³⁾ partially removed during processing

Example 14:

Round, slightly bi-convex, film-coated tablets with beveled edges:

Component	Amount per unit [mg]
Table Core	
Fluvastatin Sodium ¹⁾	84.24 ²⁾
Cellulose Microcrystalline / Micro-crystalline cellulose fine powder	111.27
Hypromellose / Hydroxypropyl methyl cellulose (Methocel K100LVP CR; HPMC100 cps)	97.50
Hydroxypropyl cellulose (Klucel HXF)	16.25
Potassium hydrogen carbonate / Potassium bicarbonate	8.42
Povidone	4.88
Magnesium stearate	2.44
Core Tablet Weight	325.00
Coating	
Coating premix - Opadry Yellow (00F22737)	9.75
Total Weight	334.75
Water, purified ³⁾	Q.S.

¹⁾ 84.24 mg of the sodium salt of fluvastatin is equivalent to 80 mg of fluvastatin free acid

²⁾ to be adjusted for moisture (LOD)

³⁾ removed during processing


Example 15 :

Round, biconvex, beveled-edged, film-coated tablets


Component	Unit wt./Vol. [mg]	Unit wt./Vol. [mg]	Unit wt./Vol. [mg]	Unit wt./Vol. [mg]
Benazepril Hydrochloride	5.00	10.00	20.00	40.00
Lactose Monohydrate, NF	142.00	132.00	117.00	97.00
Pregelatinized Starch, NF	8.00	8.00	8.00	8.00
Colloidal Silicon Dioxide, NF (Cab-O-Sil, M-5)	1.00	1.00	1.00	1.00
Crospovidone, NF	3.00	3.00	3.00	3.00
Microcrystalline Cellulose, NF	18.00	18.00	18.00	24.25
Hydrogenated Castor Oil, NF	8.00	8.00		
Magnesium Stearate, NF			8.00	1.75
Color:	-			0.50
Yellow-Brown (suspension)		2.00		
Red-Brown (suspension)			0.50	
Purified Water, USP	trace	trace	trace	trace
Opadry Color:				
Yellow	8.38	8.38		
Pink			8.38	8.38
Total	193.38	190.38	183.88	183.88

What is claimed is


1. Use of a combination of at least two therapeutic combination components selected from the group consisting of
 - (i) an AT₁-receptor antagonist or an AT₁ receptor antagonist combined with a diuretic or, in each case, a pharmaceutically acceptable salt thereof,
 - (ii) a HMG-Co-A reductase inhibitor or a pharmaceutically acceptable salt thereof and
 - (iii) an ACE inhibitor or a pharmaceutically acceptable salt thereof;for the manufacture of a medicament for the prevention of, delay of progression of, treatment of a disease or condition selected from the group consisting of hyperlipidaemia and dyslipidemia, atherosclerosis, insulin resistance and syndrome X, diabetes mellitus type 2, obesity, nephropathy, renal failure, hypothyroidism, survival post MI, coronary heart diseases, hypertension in the elderly, familial dyslipidemic hypertension, and remodeling following hypertension (antiproliferative effect of the combination), all these diseases or conditions associated with or without hypertension, and, furthermore, for the prevention of, delay of progression of, treatment of stroke, erectile dysfunction and vascular disease.
2. Use according to claim 1 wherein said AT₁-receptor antagonist is selected from the group consisting of valsartan, losartan, candesartan, eprosartan, irbesartan, saprisartan, tasosartan, telmisartan, the compound with the designation E-1477 of the following formula



the compound with the designation SC-52458 of the following formula



and the compound with the designation ZD-8731 of the following formula



or, in each case, a pharmaceutically acceptable salt thereof.

3. Use according to claim 2 wherein said AT₁-receptor antagonist is valsartan or a pharmaceutically acceptable salt thereof.
4. Use according to any one of claims 1 to 3 wherein said HMG-Co-A reductase inhibitor is selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin, or, in each case, a pharmaceutically acceptable salt thereof.
5. Use according to claim 4 wherein said HMG-Co-A reductase inhibitor is fluvastatin, atorvastatin, pitavastatin or simvastatin.
6. Use according to any one of claims 1 to 5 wherein said ACE inhibitor is selected from the group consisting of alacepril, benazepril, benazeprilat, captopril, ceronapril, cilazapril, delapril, enalapril, enaprilat, fosinopril, imidapril, lisinopril, moveltopril, perindopril, quinapril,

ramipril, spirapril, temocapril, and trandolapril, or, in each case, a pharmaceutically acceptable salt thereof.

7. Use according to claim 6 wherein said ACE inhibitor is benazepril or enalapril or a pharmaceutically acceptable salt thereof.

8. Use of a therapeutic agent selected from the group consisting of

(i) an AT_1 -receptor antagonist or an AT_1 receptor antagonist combined with a diuretic or, in each case, a pharmaceutically acceptable salt thereof,

(ii) a HMG-Co-A reductase inhibitor or a pharmaceutically acceptable salt thereof and

(iii) an ACE inhibitor or a pharmaceutically acceptable salt thereof,

for the manufacture of a medicament for the prevention of, delay of progression of or treatment of endothelial dysfunction with or without hypertension.

9. A pharmaceutical composition for the prevention of, delay of progression of, treatment of a disease or condition selected from the group consisting of hyperlipidaemia and dyslipidemia, atherosclerosis, insulin resistance and syndrome X, diabetes mellitus type 2, obesity, nephropathy, renal failure, hypothyroidism, survival post MI, coronary heart diseases, hypertension in the elderly, familial dyslipidemic hypertension, and remodeling following hypertension (antiproliferative effect of the combination), all these diseases or conditions associated with or without hypertension, and, furthermore, in the prevention of, delay of progression of, treatment of stroke, erectile dysfunction and vascular disease, comprising

(a) a combination of at least two therapeutic combination components selected from the group consisting of

(i) an AT_1 -receptor antagonist or an AT_1 receptor antagonist combined with a diuretic or, in each case, a pharmaceutically acceptable salt thereof,

(ii) a HMG-Co-A reductase inhibitor or a pharmaceutically acceptable salt thereof and

(iii) an ACE inhibitor or a pharmaceutically acceptable salt thereof, and

(b) a carrier.

10. A method of prevention of, delay of progression of or treatment of endothelial dysfunction with or without hypertension comprising administering to a warm-blooded animal, including man, in need thereof an effective amount of

- (a) an AT₁ receptor antagonist or an AT₁ receptor antagonist combined with a diuretic or, in each case, a pharmaceutically acceptable salt thereof;
- (b) a HMG-Co-A reductase inhibitor or a pharmaceutically acceptable salt thereof;
- (c) an ACE inhibitor or a pharmaceutically acceptable salt thereof; or
- (d) a combination of at least two therapeutic combination components selected from the group consisting of
 - (i) an AT₁-receptor antagonist or an AT₁ receptor antagonist combined with a diuretic or, in each case, a pharmaceutically acceptable salt thereof,
 - (ii) a HMG-Co-A reductase inhibitor or a pharmaceutically acceptable salt thereof and
 - (iii) an ACEI inhibitor or a pharmaceutically acceptable salt thereof.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 October 2001 (18.10.2001)

PCT

(10) International Publication Number
WO 01/076573 A3

- (51) International Patent Classification⁷: **A61K 31/41**, 31/40, 31/55, A61P 9/08, 9/10
- (74) Agent: **BECKER, Konrad**; Novartis AG, Corporate Intellectual Property, Patent & Trademark Dept., CH-4002 Basel (CH).
- (21) International Application Number: PCT/EP01/04115
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date: 10 April 2001 (10.04.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/196,743 12 April 2000 (12.04.2000) US
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except AT, US*): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).
- Published:
— with international search report
- (71) Applicant (*for AT only*): **NOVARTIS-ERFINDUNGEN** [AT/AT]; VERWALTUNGSGESELLSCHAFT m.b.H., Brunner Strasse 59, A-1235 Vienna (AT).
- (88) Date of publication of the international search report:
17 April 2003
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **DE GASPARO, Marc** [CH/CH]; Es Planches 123a, CH-2842 Rossemaison (CH). **GRAVES, Kurt, C.** [US/US]; 4 Woodhull Drive, Chester, NJ 07930 (US).
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: COMBINATION OF AT LEAST TWO COMPOUNDS SELECTED FROM AN AT₁-RECEPTOR ANTAGONIST OR AN ACE INHIBITOR OR A HMG-CO-A REDUCTASE INHIBITOR GROUPS

(57) Abstract: The invention relates to a combination of at least two therapeutic combination components selected from the group consisting of (i) an AT₁-receptor antagonist or an AT₁ receptor antagonist combined with a diuretic or, in each case, a pharmaceutically acceptable salt thereof, (ii) a HMG-Co-A reductase inhibitor or a pharmaceutically acceptable salt thereof and (iii) an ACE inhibitor or a pharmaceutically acceptable salt thereof for use in the prevention of, delay of progression of, treatment of selected diseases and conditions.



WO 01/076573 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/04115

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/41 A61K31/40 A61K31/55 A61P9/08 A61P9/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, EP0-Internal, BIOSIS, MEDLINE, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 930 076 A (SANKYO CO) 21 July 1999 (1999-07-21) claims 1-6,24-26 ---	1-3,6,7, 9
X	WO 97 36874 A (SMITHKLINE BEECHAM CORP ;DUDDU SARMA (US); PALEPU NAGESWARA R (US)) 9 October 1997 (1997-10-09) page 1, line 12; claims 11-13,20,21,42-47 page 8, line 20-32 ---	1-3,6,7, 9
X	WO 96 31234 A (CIBA GEIGY AG ;GASPARO MARC DE (CH); WEBB RANDY LEE (US); COHEN DA) 10 October 1996 (1996-10-10) page 1, paragraph 2; claims 1,2 --- -/-	1-3,6,7, 9

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

22 May 2002

Date of mailing of the international search report

25.07.02

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Luangkhot, N

INTERNATIONAL SEARCH REPORT

International Application No

PC/EP 01/04115

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 02032 A (MERCK & CO INC ;MERCK SHARP & DOHME CHIBRET SN (FR); REMUZZI GIUSE) 23 January 1997 (1997-01-23) page 2, line 7-24; claims 1,2,4,7-12 page 3, line 19-25 ---	1-3,6,7, 9
X	US 5 981 470 A (AHMED ASIF SYED) 9 November 1999 (1999-11-09) column 8, line 33-39; claims 1-3 ---	1-3,6,7, 9
X	RUILOPE L M ET AL: "SAFETY OF THE COMBINATION OF VALSARTAN AND BENAZEPRIL IN PATIENTS WITH CHRONIC RENAL DISEASE" JOURNAL OF HYPERTENSION, CURRENT SCIENCE, PHILADELPHIA, PA, US, vol. 18, no. 1, January 2000 (2000-01), pages 89-95, XP001056854 ISSN: 0263-6352 abstract ---	1-3,6,7, 9
X	MERVAALA, EERO ET AL: "Angiotensin-converting enzyme inhibition and AT1 receptor blockade modify the pressure-natriuresis relationship by additive mechanisms in rats with human renin and angiotensinogen genes." JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, (AUG., 1999) VOL. 10, NO. 8, PP. 1669-1680., XP001071075 abstract ---	1-3,6,7, 9
X	DE GASPARO, MARC (1) ET AL: "Protective effects of the combination of non hypotensive doses of valsartan and enalapril in spontaneously hypertensive rats with endothelial dysfunction." JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY., (FEB., 2000) VOL. 35, NO. 2 SUPPL. A, PP. 248A. MEETING INFO.: 29TH ANNUAL SCIENTIFIC SESSION OF THE AMERICAN COLLEGE OF CARDIOLOGY. ANAHEIM, CALIFORNIA, USA MARCH 12-15, 2000, XP001061413 the whole document -----	1-3,6,7, 9

INTERNATIONAL SEARCH REPORT

International application No.
● PCT/EP 01/04115**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 10
because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
2. ☒ Claims Nos.: -
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1 (partly), 2-3, 6-7 and 9 (partly)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

The use of wording in present claim 1 such as AT1 receptor antagonist, diuretic and ACE inhibitor relates to an extremely large number of possible compounds. Because of the use of functional definition, it is likely that all the compounds falling within the scope of the definition can not be searched.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1(partly), 2-3, 6-7 and 9(partly)

Use of a combination comprising an AT1-receptor antagonist eventually combined with a diuretic, and an ACE inhibitor for the manufacture of a medicament for the treatment of the diseases claimed in claim 1

2. Claims: 1(partly), 2-3, 4-5 and 9(partly)

Use of a combination comprising an AT1-receptor antagonist eventually combined with a diuretic, and a HMG-Co-A reductase inhibitor for the manufacture of a medicament for the treatment of the diseases claimed in claim 1

3. Claims: 1(partly), 4-5, 6-7 and 9(partly)

Use of a combination comprising a HMG-CoA reductase inhibitor, and an ACE inhibitor for the manufacture of a medicament for the treatment of the diseases claimed in claim 1

4. Claim : 8(partly)

Use of an AT1-receptor antagonist eventually combined with a diuretic for the manufacture of a medicament for the treatment of the diseases claimed in claim 8

5. Claim : 8(partly)

Use of an ACE inhibitor for the manufacture of a medicament for the treatment of the diseases claimed in claim 8

6. Claim : 8(partly)

Use of a HMG-CoA reductase inhibitor for the manufacture of a medicament for the treatment of the diseases claimed in claim 8

INTERNATIONAL SEARCH REPORT

International Application No

PC EP 01/04115

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0930076	A	21-07-1999	AU 714618 B2	06-01-2000
			AU 3459597 A	09-02-1998
			EP 0930076 A1	21-07-1999
			HU 9903166 A2	28-09-2000
			NO 990166 A	15-03-1999
			NZ 333723 A	29-09-2000
			US 2002013308 A1	31-01-2002
			CA 2261040 A1	22-01-1998
			CN 1230122 A	29-09-1999
			CZ 9900102 A3	16-06-1999
			EP 1175902 A1	30-01-2002
			WO 9802183 A1	22-01-1998
			JP 10081632 A	31-03-1998

WO 9736874	A	09-10-1997	AP 901 A	23-11-2000
			AU 726694 B2	16-11-2000
			AU 2547097 A	22-10-1997
			BG 102822 A	30-11-1999
			BR 9708336 A	03-08-1999
			CN 1332167 A	23-01-2002
			CN 1214682 A	21-04-1999
			CZ 9803101 A3	17-03-1999
			EP 0889880 A1	13-01-1999
			HU 9902769 A2	28-03-2000
			JP 2000508632 T	11-07-2000
			NO 984503 A	28-09-1998
			NZ 332008 A	28-05-1999
			PL 329046 A1	01-03-1999
			SK 132298 A3	10-03-1999
			TR 9801954 T2	21-12-1998
			TW 434239 B	16-05-2001
			WO 9736874 A1	09-10-1997
			US 2001031877 A1	18-10-2001
			ZA 9702686 A	29-09-1997

WO 9631234	A	10-10-1996	AU 5399096 A	23-10-1996
			BR 9604818 A	09-06-1998
			CA 2214143 A1	10-10-1996
			CN 1181019 A	06-05-1998
			CZ 9703138 A3	14-01-1998
			WO 9631234 A1	10-10-1996
			EP 0820302 A1	28-01-1998
			HU 9801593 A2	28-01-1999
			JP 11503139 T	23-03-1999
			NO 974400 A	23-09-1997
			PL 322529 A1	02-02-1998
			SK 133897 A3	04-02-1998
			TR 9701121 T1	21-03-1998

WO 9702032	A	23-01-1997	AU 716519 B2	24-02-2000
			AU 6291696 A	05-02-1997
			CA 2224451 A1	23-01-1997
			EP 0835106 A1	15-04-1998
			JP 11508894 T	03-08-1999
			WO 9702032 A1	23-01-1997

US 5981470	A	09-11-1999	AU 699747 B2	10-12-1998
			AU 2625595 A	04-01-1996

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/04115

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5981470	A	CA 2192061 A1	14-12-1995
		EP 0764021 A1	26-03-1997
		WO 9533454 A1	14-12-1995
		JP 10501799 T	17-02-1998
